The Latest Cardiac and Vascular News
LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: 2020 highlights and results Global strategic partnership with Nestlé Health Science for the development and marketing of TOTUM-63, a plant-based active substance with clinically proven metabolic health benefits in prediabetic subjects. Launch of REVERSE-IT, a global pivotal Phase II/III clinical trial of TOTUM-63 for reducing […]
–Galaxy’s proprietary CENTAURI™ system on track for EU registration and US pivotal trial start later this year; shows best-in-class potential SAN CARLOS, Calif., March 16, 2021 /PRNewswire/ — ATP, a leader in life science venture capital, announced today $18M in Series A financing for its portfolio company Galaxy Medical, Inc. The funds are being […]
COPENHAGEN, Denmark, March 16, 2021 /PRNewswire/ — CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, is announcing a change to its Board of Directors. Meghna Eichelberger, Partner and Associate Director of Medical Technologies, at The Boston Consulting Group (BCG), has joined CathVision’s Board […]
Provides overview of bentracimab development program during virtual Investor & Analyst Day, March 15, 2021, 12 – 2 pm ET Announced commercial supply agreement with BioVectra to support the development and commercialization of lead product candidate bentracimab Expanded pivotal Phase 3 REVERSE-IT trial of bentracimab into Canada and the European […]
DUBLIN, Ohio, March 12, 2021 /PRNewswire/ — Cardinal Health (NYSE: CAH) today announced that it has signed a definitive agreement to sell its Cordis business to Hellman & Friedman (H&F) for approximately $1 billion, which includes buyer’s assumption of certain liabilities and seller’s retention of certain working capital accounts. The transaction is expected to close […]
VANCOUVER and MINNEAPOLIS, March 11, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today reported financial results for the fourth quarter and fiscal year ended December 31, 2020. Fourth Quarter Highlights Generated revenue of $514,000 in the quarter and $1.96 million for the full year as Reducer […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc. announced today that Lisa Anderson, Ph.D., has been elevated to the role of CEO. Dr. Anderson succeeds William Edelman, who has served as Chairman and CEO since 2012 and recently announced his retirement. John Cammett, member of the Board for over three years, will assume the […]
MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a commercial scale supply agreement for the production of bentracimab, PhaseBio’s […]
WARREN, N.J., March 11, 2021 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2020. “Bellerophon continues […]
– Dr. Hans-Peter Stoll is an interventional cardiologist and senior medical executive with 20 years of leadership experience who has demonstrated deep expertise in clinical strategy and execution. – Dr. Stoll supports and expands MCRA’s specialization in cardiology and clinical trial management globally. WASHINGTON, March 11, 2021 /PRNewswire/ — MCRA, LLC, a […]
